Latest & greatest articles for meloxicam

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on meloxicam or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on meloxicam and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for meloxicam

1. Bupivacaine / meloxicam (Zynrelef)

Bupivacaine / meloxicam (Zynrelef) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/497953/2020 EMEA/H/C/005205 Zynrelef (bupivacaine / meloxicam) An overview of Zynrelef (...) and why it is authorised in the EU What is Zynrelef and what is it used for? Zynrelef is a painkiller used in adults to reduce pain from small to medium-sized wounds after an operation. It contains the active substances bupivacaine and meloxicam. How is Zynrelef used? Zynrelef is a prolonged-release solution that is applied to the wound during surgery before the wound is closed. Prolonged-release means that the active substances are released slowly over several hours after application. The medicine

2020 European Medicines Agency - EPARs

2. Analgesic Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-Severe Pain After Open Abdominal Hysterectomy: A Phase 2 Randomized Clinical Trial (Full text)

Analgesic Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-Severe Pain After Open Abdominal Hysterectomy: A Phase 2 Randomized Clinical Trial

2019 EvidenceUpdates PubMed abstract

3. Efficacy and Safety of Intravenous Meloxicam in Patients With Moderate-to-Severe Pain Following Bunionectomy: A Randomized, Double-Blind, Placebo-controlled Trial (Abstract)

Efficacy and Safety of Intravenous Meloxicam in Patients With Moderate-to-Severe Pain Following Bunionectomy: A Randomized, Double-Blind, Placebo-controlled Trial To evaluate the analgesic efficacy and safety of a novel intravenous (IV) formulation of meloxicam (30 mg) in patients with moderate-to-severe pain following a standardized, unilateral bunionectomy with first metatarsal osteotomy and internal fixation.Patients who met the criteria for moderate-to-severe postoperative pain were (...) randomized to receive bolus injections of meloxicam IV 30 mg (n=100) or placebo (n=101) administered once daily. The primary efficacy endpoint was the Summed Pain Intensity Difference over 48 hours (SPID48). Secondary efficacy endpoints included sum of time-weighted pain intensity differences (SPID) values at other timepoints/intervals, time to first use of rescue analgesia, and number of rescue doses taken. Safety assessments included the incidence of adverse events (AEs), physical examinations

2018 EvidenceUpdates

4. Meloxicam

Meloxicam Top results for meloxicam - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for meloxicam The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

5. Evaluation of the safety and efficacy of an intravenous nanocrystal formulation of meloxicam in the management of moderate-to-severe pain after bunionectomy (Full text)

Evaluation of the safety and efficacy of an intravenous nanocrystal formulation of meloxicam in the management of moderate-to-severe pain after bunionectomy This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of an intravenous (IV) nanocrystal formulation of meloxicam in subjects with moderate-to-severe pain following a standardized unilateral bunionectomy.Fifty-nine subjects aged 18-72 years were randomized to receive doses of either 30 mg (n=20) or 60 mg (...) (n=20) meloxicam IV or placebo (n=19), administered once daily as bolus IV injections over 15-30 seconds (two or three doses). Safety, the primary objective, was assessed by physical examination, clinical laboratory tests, and the incidence of adverse events (AEs). Efficacy was evaluated by examining summed pain intensity differences over the first 48 hours (SPID48) using analysis of covariance models. Use of opioid rescue analgesic agents was evaluated.Generally, AEs were mild-to-moderate

2018 EvidenceUpdates Controlled trial quality: predicted high PubMed abstract

6. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. (Abstract)

The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Non-steroidal anti-inflammatory drugs (NSAIDs) are known to increase the risk of cardiovascular (CV) and renal incidences, especially at higher doses and upon long term use. However, the available reports are criticized for lack of specificity, grouping of vastly different outcomes together and ignoring the heterogeneity among NSAIDs. In this systematic review, we are reporting CV/renal (...) risks associated with meloxicam, stratified into myocardial, vascular, renal risk categories, to address the differential nature of NSAIDs effects on different body systems. We are also reporting composite CV/renal risk to present overall risk associated with various covariates.We searched the online healthcare databases for observational studies or randomized controlled trials, reporting myocardial or all-cause mortality outcome (>90 days exposure) and/or vascular/renal outcomes (any exposure

2015 Inflammopharmacology

7. Meloxicam

Meloxicam USE OF MELOXICAM IN PREGNANCY 0344 892 0909 USE OF MELOXICAM IN PREGNANCY (Date of issue: July 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) used to treat (...) pain and inflammation in rheumatic disease, short-term exacerbation of osteoarthritis and ankylosing spondylitis. There are no published data available regarding exposure to meloxicam during human pregnancy. NSAID use in pregnancy has been associated with increased risks of various different congenital malformations, including cardiovascular defects and oral clefts, as well as an increased risk of spontaneous abortion. However, the available data are conflicting and limited, and firm associations

2014 UK Teratology Information Service

8. Single dose oral meloxicam for acute postoperative pain in adults. (Full text)

Single dose oral meloxicam for acute postoperative pain in adults. Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) used mainly in treating pain associated with arthritis. The usual oral dose for osteoarthritis is 15 mg daily, but lower doses of 7.5 mg are advised in older patients. This review sought to evaluate the efficacy and safety of oral meloxicam in acute postoperative pain, using clinical studies of patients with established pain, and with outcomes measured primarily over 6 (...) hours using standard methods. This type of study has been used for many decades to establish that drugs have analgesic properties.To assess the efficacy of single dose oral meloxicam in acute postoperative pain, and any associated adverse events.We searched Cochrane CENTRAL (Issue 2, 2009), MEDLINE (June 2009); EMBASE (June 2009); the Oxford Pain Relief Database.Randomised, double-blind, placebo-controlled clinical trials of oral meloxicam for relief of acute postoperative pain in adults.Two review

2009 Cochrane PubMed abstract

9. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. (Full text)

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. To review the clinical effectiveness and cost-effectiveness of cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDs) (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis (OA (...) )', which includes an initial drug switching cycle, and the 'simpler AGM', where there is no initial cycle and no opportunity for the patient to switch NSAID.Compared with non-selective NSAIDs, the COX-2 selective NSAIDs were found to be equally as efficacious as the non-selective NSAIDs (although meloxicam was found to be of inferior or equivalent efficacy) and also to be associated with significantly fewer clinical upper gastrointestinal (UGI) events (although relatively small numbers of clinical

2008 Health technology assessment (Winchester, England) PubMed abstract

10. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Cyclooxygenase-2 (...) selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Chen Y F, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor R S CRD summary This review evaluated the effectiveness of cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDS) for osteoarthritis (OA) and rheumatoid arthritis (RA) patients

2008 DARE.

11. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Cyclooxygenase-2 (...) selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Chen Y-F, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Chen

2008 Health Technology Assessment (HTA) Database.

12. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam

Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac modified-release and piroxicam for 4 weeks, in the treatment of patients with osteoarthritis. The doses studied were 7.5 mg meloxicam once daily, 100 mg diclofenac

2003 NHS Economic Evaluation Database.

13. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis

Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis National Institute (...) for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 27. 2001

2001 Health Technology Assessment (HTA) Database.

14. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials

Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials Schoenfeld P Authors' objectives To review the frequency and severity of adverse gastrointestinal (GI) events among patients using meloxicam (...) , a cyclooxygenase (COX)-2-selective nonsteroidal anti-inflammatory drug (NSAID). Searching Two independent searches of MEDLINE (1990 to 1998) were made using the MeSH terms: 'meloxicam', 'NSAIDs', 'GI bleeding', 'ulcer', 'dyspepsia', 'GI complication', 'randomized (pt)', 'meta-analysis (pt)', and 'clinical trial'. The authors also scanned the bibliographies of all retrieved studies and searched the abstracts of the American Gastrointestinal Association and the American Society for Gastrointestinal Endoscopy

1999 DARE.

15. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. (Abstract)

Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. This article provides a systematic review of the frequency and severity of adverse gastrointestinal (GI) events among patients using meloxicam, a cyclooxygenase (COX)-2-selective nonsteroidal anti-inflammatory drug (NSAID). A MEDLINE search of English language articles from 1990-1998, a manual search of citations from primary trials and review articles, and a manual search (...) of proceedings from international gastroenterology meetings were conducted. Randomized clinical trials comparing the frequency of GI adverse events for meloxicam versus non-COX-2-selective NSAIDs were selected. Specific data about the frequency of dyspepsia; perforations, ulcers, and bleeds (PUBs); and withdrawal of medication because of adverse GI events was also extracted. From a pool of 62 potentially relevant citations, 12 randomized trials were identified. All trials concerning symptomatic GI adverse

1999 The American journal of medicine

16. Economic evaluation of meloxicam (7.5mg) versus sustained release diclofenac (100mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK

Economic evaluation of meloxicam (7.5mg) versus sustained release diclofenac (100mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK Economic evaluation of meloxicam (7.5mg) versus sustained release diclofenac (100mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK Economic evaluation of meloxicam (7.5mg) versus sustained release diclofenac (100mg) treatment for osteoarthritis: a cross-national assessment for France (...) , Italy and the UK Jansen, Capri S, Nuijten M J, Burrell, Marini M G, Hardens M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two non-steroidal anti-inflammatory drugs (NSAIDs) were evaluated: meloxicam (7.5 mg/day) versus

1997 NHS Economic Evaluation Database.